Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant pilot study in obstructive sleep apnea syndrome with arterial hypertension
2022-001900-17Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of aprepitant in hypertension (HTN) and obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Rouen University Hospital. Primary endpoint: Effect on aldosterone secretion. Started Aug 2022; status: active.
02
Drugs
aprepitant
03
Conditions
hypertension (HTN)obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2022-001900-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001900-17.